Paulina Palazzo, née Szymanska’s Post

🩸 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐫𝐮𝐠𝐬 𝐚𝐧𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐟𝐨𝐫 𝐇𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬! 🩸 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/d2YysCsm The market for drugs and diagnostics aimed at hematological disorders is witnessing remarkable growth, driven by advancements in medical technology, increasing prevalence of hematological conditions, and a growing focus on personalized medicine. Here’s a closer look at this dynamic market: 1️⃣ Rising Incidence of Hematological Disorders: Hematological disorders, including leukemia, lymphoma, anemia, and coagulation disorders, represent a significant burden on global healthcare systems. The increasing incidence of these conditions, coupled with aging populations and lifestyle factors, is driving demand for innovative drugs and diagnostics for early detection, treatment, and management. 2️⃣ Precision Medicine Approaches: Advances in genomic sequencing, molecular diagnostics, and targeted therapies have revolutionized the management of hematological disorders. Personalized medicine approaches, which tailor treatment regimens to individual patient profiles based on genetic and molecular characteristics, are transforming the landscape of hematological care and driving the development of novel drugs and diagnostics. 3️⃣ Therapeutic Innovation: Pharmaceutical companies are investing in the research and development of new therapeutic agents for hematological disorders, including targeted therapies, immunotherapies, and gene therapies. These innovative treatments offer improved efficacy, reduced side effects, and better patient outcomes, driving market growth and expanding treatment options for hematological conditions. 5️⃣ Market Expansion Opportunities: The global market for drugs and diagnostics in hematological disorders is poised for significant expansion, driven by increasing investment in research and development, growing demand for personalized medicine solutions, and rising healthcare expenditure worldwide. Market players are leveraging strategic collaborations, partnerships, and mergers to capitalize on emerging opportunities and address unmet needs in the hematological care continuum. #Company Abbott Pfizer Amgen Beckman Coulter Diagnostics Mindray Roche Biorad Medisys Pvt Ltd Eli Lilly and Company Sysmex Corporation Bristol Myers Squibb Siemens Nihon Kohden America #Type Analyzers Reagents #Application Hospital Clinic Others #Hematology #PrecisionMedicine #InnovativeTherapies #Diagnostic

🔬 Exciting Opportunity for Researchers in Drug Delivery Systems! 🔬 We're thrilled to announce the call for contributions to the Special Issue titled "Liposomes Applied in Drug Delivery Systems" in the renowned Pharmaceutics journal. This issue is edited by Dr. Pedro Fonte, Dr. Teresa Esteves, and Dr. Sofia Duarte. 🌟 What's the Focus? This Special Issue delves into the innovative world of liposome technology in drug delivery, spotlighting its critical role in targeted therapy and diagnostics. The emergence of liposomes has revolutionized pharmaceutical research, and this issue aims to showcase the latest advances in this dynamic field. 🔍 Topics of Interest: ·        Design and synthesis of liposomes ·        Advancements in targeted drug delivery using liposomes ·        Liposomes in gene therapy ·        Innovations in liposomal formulations for drug stability ·        Applications in cancer therapy, regenerative medicine, and more 📅 Submission Deadline: 30 September 2024 🌐 Learn More and Submit: Don't miss this chance to contribute to an important discussion in the realm of nanomedicine. For detailed information, visit the Special Issue page: https://lnkd.in/dj6dW2cb 💡 Why Contribute? Your research will gain open access and high visibility, benefit from a rapid peer-review process, and receive a complimentary English editing service post-acceptance. 📝 Call for Abstracts: We invite you to send a short tentative abstract (100–150 words) describing your research within the next month. For any inquiries or to submit your abstract, please reach out to us or the Assistant Editor, Ms. Cynthia He, at cynthia.he@mdpi.com or pharmaceutics@mdpi.com. We're excited to see your innovative contributions and insights in this vital area of nanomedicine. Let's advance the field together! Warm regards, Dr. Pedro Fonte (prfonte@ualg.pt), Dr. Teresa Esteves (teresa.esteves@tecnico.ulisboa.pt), Dr. Sofia de Oliveira Dias Duarte (sofia.duarte@tecnico.ulisboa.pt) #DrugDelivery #Liposomes #Pharmaceutics #Research #CallForPapers #Nanomedicine #TargetedTherapy #Pharmaceuticals

𝐒𝐚𝐧𝐠𝐚𝐦𝐨 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐋𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐆𝐞𝐧𝐞𝐧𝐭𝐞𝐜𝐡 𝐟𝐨𝐫 𝐍𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) Sangamo Therapeutics, Inc. has entered a license agreement with Genentech Genentech, a Roche Group member, to develop intravenous genomic medicines for neurodegenerative diseases. Sangamo granted Genentech an exclusive license to its zinc finger repressors targeting the tau gene, involved in Alzheimer's disease, and an undisclosed second neurology target. Genentech will also use Sangamo’s neurotropic AAV capsid, STAC-BBB, which shows strong blood-brain barrier penetration. “Sangamo has been pioneering genomic medicine to address neurodegenerative diseases,” said Sandy Macrae Sandy Macrae, MRCP PhD, CEO of Sangamo. “Our zinc finger technology and STAC-BBB capsid can potentially address challenges in delivering CNS therapeutics. We are excited to partner with Genentech to advance treatment options for neurodegenerative disorders.” Boris L. Zaïtra Boris L. Zaïtra, Head of Roche Corporate Business Development, added, “With our expertise in neurological research, we are exploring transformative approaches like gene therapy for neurodegenerative diseases. Our partnerships, such as with Sangamo, aim for breakthroughs in early diagnosis and treatment.” Under the agreement, Sangamo will complete a technology transfer and certain preclinical activities, while Genentech handles clinical development, regulatory interactions, manufacturing, and global commercialization. Sangamo will receive $50 million in near-term upfront fees and milestone payments and is eligible for up to $1.9 billion in development and commercial milestones, plus tiered royalties. Sangamo is also discussing further partnerships for its STAC-BBB capsid delivery platform, epigenetic regulation capabilities, and other assets, including Fabry disease. #GenomicMedicine #LicensingAgreement #NeurodegenerativeDiseases #Biotech #HealthcareInnovation #GeneTherapy #Pharmaceuticals #AlzheimersResearch #Biotechnology #MedicalResearch #Healthcare

Precision Medicine Market Worth $50.2 Billion Download a PDF Brochure: https://lnkd.in/dJePPRqR Precision Medicine Market by Type (Inhibitors, Monoclonal Antibodies, Cell & Gene Therapy, Antivirals, Antiretroviral), Indication (Oncology, Rare diseases, Hematology, Infectious), End user (Hospitals & Clinics, Home care) - Global Forecast to 2028 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Wohlfahrtsstiftung der F. Hoffmann-La Roche AG Novartis Bristol Myers Squibb Gilead Sciences AstraZeneca Pfizer AbbVie Eli Lilly and Company GlaxoSmithKline Consumer Healthcare, L.P. Sanofi Johnson & Johnson Merck KGaA, Darmstadt, Germany Amgen TakedaPharmaceutical Nordics AB Other Companies that are Operating in this Market Globally: Precision For Medicine Precision Medicine Group Servier Guardant Health Integra Connect  Myriad Genetics Tempus AI Ambry Genetics Caris Life Sciences  Q² Solutions Novanta Inc. Amplity Health Discovery Life Sciences SpringWorks Therapeutics BioIVT Velsera CorEvitas, LLC Castle Biosciences, Inc. Quantori Invivoscribe Mindful Health Solutions  MGI #PrecisionMedicine #HealthTech #MedicalInnovation #PersonalizedMedicine #HealthcareInnovation #Genomics #MedicalTechnology #PatientCare #HealthcareSolutions #Biotechnology #ClinicalDiagnostics #GeneticTesting #MedicalResearch #Pharmacogenomics #HealthcareTech #Theranostics #CancerTreatment #GenomicMedicine #ClinicalResearch #MarketResearch

We are beyond excited to announce breakthrough research unveiling the novel mechanism of action of dual signal modulators for anti-inflammatory and endothelial-stabilizing therapies published in the prestigious journal of American Society for Pharmacology and Experimental Therapeutics - ASPET. These findings mark a significant advancement in next-generation immunomodulatory therapies. The immense potential of GEn-1124 underscores our mission at GEn1E Lifesciences Inc. to develop precision therapies for inflammatory and auto-immune diseases and improve outcomes for patients suffering from devastating conditions. The study is titled "First-in-Class Mitogen-Activated Protein Kinase p38α: MAPK-Activated Protein Kinase-2 (MK2) Dual Signal Modulator with Anti-inflammatory and Endothelial-Stabilizing Properties". We would like to express our deep gratitude to co-authors Paul Shapiro, PhD, Jeffrey Hasday, MD, and other esteemed fellow authors who brought these findings to light. We remain grateful to my alma mater University of Maryland, Baltimore (UMB) for our continued partnership. #innovation #pulmonary #respiratory #dualsignalmodulator #biotech #immunomodulators #precisiontherapies #therapeutics #ARDS #AI #ML #drugdevelopment #inflammatory #autoimmune #baltimore

Everything you missed in #Pharma & #Biotech 🦠🔬 ✅ Approvals Regeneron and Sanofi’s Dupixent (dupilumab) expands label to children aged one year and older with eosinophilic esophagitis FDA orders black box warnings for CAR-T therapies based on risk of T-cell malignancies 💸 Deals Sanofi to acquire Inhibrx, Inc., adding asset for alpha-1-antitrypsin deficiency to rare diseases portfolio Kyowa Kirin International plc. acquires global gene therapy leader Orchard Therapeutics Therapeutic Solutions International launches Epilepsy Bio, adult stem cell therapy company focused on epilepsy BlueRock exercises option to license cell therapy candidate for photoreceptor diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics Bladder cancer biotech CG Oncology raises $380 million in IPO Second biotech ArriVent Biopharma, focused on bringing China-developed drugs to Western markets via in-licensing deals, raises $175M in IPO The Michael J. Fox Foundation for Parkinson's Research awards grant to Vesper Bio for advancement of candidate treating Parkinson’s disease 👀 To watch: Centers for Medicare & Medicaid Services to issue Max Fair Pricing calculations on first 10 drugs in Feb, a key IRA feature impacting access and pricing Eli Lilly and Company’s website offering telehealth prescriptions and direct home delivery of drugs, including Zepbound, to expand patient access Japan drug pricing rules encouraging earlier launches and rewarding innovation to be updated in April World Health Organization’s Fair Pricing Forum 2024 to take place online Feb 6-8 👉 What’s your favorite industry news? Hannah Kurth #pharma #biotech #PULSENews

Another great article about the shift in modern medicine and treatments. Very excited for 2024! #MucosalMelanoma #MucosalMelanomaSurvivor #CellTherapy #CellExtraction #CellExpansion #TILs #TILtherapy

𝐄𝐮𝐫𝐨𝐩𝐞 𝐂𝐞𝐥𝐥 𝐚𝐧𝐝 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/ghdEJ8Ss The Europe cell and gene therapy market, valued at USD 2.26 billion in 2023, is projected to reach USD 14.45 billion by 2034, with a robust CAGR of 36.26% during this period. This growth is driven by heightened interest from biopharmaceutical companies, an increasing number of regenerative medicine firms, greater financing, and supportive government policies, including prime designations and RMAT regulations. Furthermore, the expansion is fueled by the growing application of new products in clinical trials, rising demand for comprehensive solutions for severe diseases, and increased healthcare spending in European countries on cell and gene therapy products. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐏𝐫𝐨𝐝𝐮𝐜𝐭: Cell Therapy and Gene Therapy ▶𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Others ▶𝐄𝐧𝐝-𝐮𝐬𝐞𝐫: Hospitals, Cancer Care Centers, and Others. ▶𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐲: North America, Europe, APAC, Latin America, and Middle East & Africa. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝:          Novartis, Gilead Sciences, Amgen, Roche, Orchard Therapeutics - U.S., BioMarin Pharmaceutical Inc., PTC Therapeutics, Inc., Bristol Myers Squibb, Organogenesis, Smith+Nephew, Legend Biotech, CSL, Vertex Pharmaceuticals, and Human Stem Cells Institute. #CellTherapy #GeneTherapy #GeneticMedicine #CellAndGeneTherapy #AdvancedTherapies #GeneticEngineering #BiotechInnovation #CellTherapyResearch #GeneEditing #CRISPR #CAR_Therapy #GeneEditingTechnologies #RegenerativeMedicine #PersonalizedMedicine #CellTherapyAdvancements #GeneTherapyBreakthroughs #CellAndGeneTech #BioPharma #TherapeuticAdvances #NextGenTherapies

🔍 "Navigating the Complexities of Cell and Gene Therapy in Advanced Therapy Medicinal Products (ATMPs) Clinical Trials" With over 30 years in the pharmaceutical industry, I've seen firsthand the evolution of medical treatments and the critical importance of continuous learning. That's why I'm thrilled to invite my fellow pharma professionals to an educational course that could redefine your approach to modern therapies. 📅 Dates & Sessions: EU Edition: April 22-23, 2024 (9:00 am - 1:00 pm UTC+1) USA Edition: April 18-19, 2024 (9:00 am - 1:00 pm UTC-5) This course isn't just another training; it's a deep dive into the groundbreaking realm of ATMP clinical trials, including cell and gene therapies. It's designed to enrich your understanding of Good Clinical Practice (GCP) while focusing on the unique challenges and opportunities presented by ATMPs. ✨ Key Highlights: Insightful sessions led by Jessica Cordes, a renowned clinical research consultant with a 15-year track record in drug development, especially in oncology and cell and gene therapies. An in-depth exploration of sponsor and investigator responsibilities, risk-based approaches, and the Quality by Design (QbD) concept within ATMPs. Designed for professionals in clinical research, regulatory affairs, and the pharmaceutical and biotechnological industries, or anyone keen on the latest in ATMP clinical trials. Don't miss this chance to stay at the forefront of pharmaceutical advancements and elevate your professional skills. Whether you're in the EU or the USA, we have a session tailored for you. 👉 For more details and registration, visit our Training Course website at : US: https://lnkd.in/dbGwCBGV EU: https://lnkd.in/d5Hi5qCC Let's embrace the future of pharma together. I look forward to connecting with many of you there and discussing how these advancements will shape our industry's future. #PharmaProfessionals #ATMPClinicalTrials #CellGeneTherapy #ProfessionalDevelopment #PharmaceuticalIndustry